Andy I. Chen

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 726 citations · Full text

Lymphoid Neoplasia, Cell Therapy, Transplantation +10

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 492 citations · Full text

Lymphoid Neoplasia, Hematology, Immunology +6

Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell:T Cell Interactions

Andy I. Chen, Alexander J. McAdam, Janet E. Buhlmann et al. · Immunity · 1999 · 312 citations · Full text

Signal Transduction, Dendritic Cell, Ox40-ligand Has +11

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani et al. · The Lancet Haematology · 2019 · 243 citations · Full text

Lymphoid Neoplasia, Pinatuzumab Vedotin, Medicine +9

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee et al. · Blood · 2018 · 237 citations · Full text